Lumbar spinal fusion using recombinant human bone morphogenetic protein in the canine. A comparison of three dosages and two carriers.

STUDY DESIGN A randomized, prospective and controlled animal study. OBJECTIVE To evaluate lumbar spinal fusion using recombinant human bone morphogenetic protein 2 in a canine model. SUMMARY OF BACKGROUND DATA Spinal fusion using autogenous bone grafting is associated with donor site morbidity and a nonunion rate of 5% to 35%. The use of recombinant human bone morphogenetic protein 2 as a bone graft substitute would eliminate donor site morbidity and perhaps augment the rate of successful fusion. METHODS Mature beagles underwent bilateral paraspinal exposure at L4-L5, followed by transverse process decortication and randomization into one of six groups using differing doses of recombinant human bone morphogenetic protein 2 implanted using either a Type I collagen carrier or a polylactic acid carrier. Two control groups were used: one group without recombinant human bone morphogenetic protein 2 and another group using autogenous rib graft alone. RESULTS Groups treated with recombinant human bone morphogenetic protein 2 demonstrated complete fusion in all animals. Animals treated with collagen carrier alone (no recombinant human bone morphogenetic protein 2) demonstrated complete absence of fusion. Successful fusion occurred in one of three canines in the autogenous bone graft group. Fusion masses in the recombinant human bone morphogenetic protein 2 treatment groups were significantly larger in size at 3 months than in the autogenous bone graft group. The collagen carrier was more biocompatible and biodegradable because residual polylactic acid carrier was seen with adjacent multinucleated giant cells. There was no evidence of spinal canal or nerve root encroachment in the recombinant human bone morphogenetic protein 2 treatment groups. CONCLUSIONS The use of recombinant human bone morphogenetic protein 2 implanted using a Type I collagen carrier resulted in 100% fusion without adverse effects.

[1]  R. Delamarter,et al.  Effective Doses of Recombinant Human Bone Morphogenetic Protein‐2 in Experimental Spinal Fusion , 1996, Spine.

[2]  W. Hutton,et al.  Morphology of the lumbar intertransverse process fusion mass in the rabbit model: a comparison between two bone graft materials--rhBMP-2 and autograft. , 1996, Journal of spinal disorders.

[3]  J. Michael Kabo,et al.  Evaluation of rhBMP‐2 With an OPLA Carrier in a Canine Posterolateral (Transverse Process) Spinal Fusion Model , 1995, Spine.

[4]  K. Chihara,et al.  Stimulatory effect of bone morphogenetic protein‐2 on osteoclast‐like cell formation and bone‐resorbing activity , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  W. Hutton,et al.  Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein‐2 , 1995, Spine.

[6]  S. Cook,et al.  In Vivo Evaluation of Recombinant Human Osteogenic Protein (rhOP-1) Implants As a Bone Graft Substitute for Spinal Fusions , 1994, Spine.

[7]  V. Rosen,et al.  The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. , 1992, The Journal of bone and joint surgery. American volume.

[8]  V. Rosen,et al.  Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Oppermann,et al.  Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. , 1990, The Journal of biological chemistry.

[10]  V. Rosen,et al.  Recombinant human bone morphogenetic protein induces bone formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Segarini,et al.  Purification and characterization of a unique osteoinductive factor from bovine bone. , 1989, The Journal of biological chemistry.

[12]  R E Booth,et al.  Harvesting Autogenous Iliac Bone Grafts: A Review of Complications and Techniques , 1989, Spine.

[13]  B. Summers,et al.  Donor site pain from the ilium. A complication of lumbar spine fusion. , 1989, The Journal of bone and joint surgery. British volume.

[14]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.

[15]  V. Rosen,et al.  Purification and characterization of other distinct bone-inducing factors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Morris,et al.  Fracture and herniation of bowel at bone graft donor site in the iliac crest. , 1984, Injury.

[17]  M. Urist,et al.  Bone cell differentiation and growth factors. , 1983, Science.

[18]  A. Reddi.  Cell biology and biochemistry of endochondral bone development. , 1981, Collagen and related research.

[19]  M. Urist,et al.  Solubilized and insolubilized bone morphogenetic protein. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Urist,et al.  Bone morphogenesis in implants of insoluble bone gelatin. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Reddi,et al.  Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Urist,et al.  Bone: Formation by Autoinduction , 1965, Science.

[23]  M. Chapman,et al.  Morbidity at bone graft donor sites. , 1989, Journal of orthopaedic trauma.

[24]  M. Urist,et al.  Intertransverse process fusion with the aid of chemosterilized autolyzed antigen-extracted allogeneic (AAA) bone. , 1981, Clinical orthopaedics and related research.

[25]  S. Lichtblau.  Dislocation of the Sacro-iliac Joint: A Complication of Bone-grafting , 1962 .